Identifying and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing.
作者信息
Jeon Youngwoo
机构信息
Lymphoma and Cell-therapy Research Center, Yeouido St. Mary's Hospital, School of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Hematology, Yeouido St. Mary's Hospital, School of Medicine, The Catholic University of Korea, Seoul, Korea.
出版信息
Korean J Intern Med. 2023 Nov;38(6):785-786. doi: 10.3904/kjim.2023.437. Epub 2023 Nov 1.
Abstract
摘要
相似文献
1
Identifying and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing.
Korean J Intern Med. 2023 Nov;38(6):785-786. doi: 10.3904/kjim.2023.437. Epub 2023 Nov 1.
2
Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing.
Korean J Intern Med. 2023 Nov;38(6):893-902. doi: 10.3904/kjim.2023.134. Epub 2023 Aug 21.
3
Application of next-generation sequencing in diffuse large B-cell lymphoma.
Pharmacogenomics. 2023 Jan;24(1):59-68. doi: 10.2217/pgs-2022-0140. Epub 2023 Jan 20.
4
Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab.
J Clin Exp Hematop. 2023 Sep 28;63(3):201-204. doi: 10.3960/jslrt.23017. Epub 2023 Jul 28.
5
Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.
Clin Cancer Res. 2016 Jun 15;22(12):2919-28. doi: 10.1158/1078-0432.CCR-15-2305. Epub 2016 Jan 27.
6
Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab.
Int J Hematol. 2009 Apr;89(3):400-402. doi: 10.1007/s12185-009-0295-4. Epub 2009 Mar 31.
7
Diffuse large B-cell lymphoma.
Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix. doi: 10.1016/j.hoc.2008.07.002.
8
Diffuse large B-cell lymphoma genotyping on the liquid biopsy.
Blood. 2017 Apr 6;129(14):1947-1957. doi: 10.1182/blood-2016-05-719641. Epub 2017 Jan 17.
9
B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
EBioMedicine. 2017 Feb;16:106-114. doi: 10.1016/j.ebiom.2017.01.027. Epub 2017 Jan 21.
10
c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.
J Pathol Clin Res. 2021 Nov;7(6):604-615. doi: 10.1002/cjp2.223. Epub 2021 Aug 9.
本文引用的文献
1
Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing.
Korean J Intern Med. 2023 Nov;38(6):893-902. doi: 10.3904/kjim.2023.134. Epub 2023 Aug 21.
2
Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas.
Blood Res. 2021 Apr 30;56(S1):S1-S4. doi: 10.5045/br.2021.2020320.
3
Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species- and GSK3β-dependent mechanism.
Br J Haematol. 2021 Feb;192(4):747-760. doi: 10.1111/bjh.17284. Epub 2021 Jan 31.
4
Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia.
Cancer Med. 2019 Feb;8(2):501-514. doi: 10.1002/cam4.1928. Epub 2019 Jan 24.
5
Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
Oncogene. 2004 Apr 29;23(20):3530-40. doi: 10.1038/sj.onc.1207336.
Zotero 插件